Health Care · Pharmaceuticals
Zoetis: revenue, profit and dividends
In fiscal 2025, Zoetis had revenue of $9.47B, up 7.1% a year on average since 2015, and net income of $2.67B (28.2% of revenue). Its dividend per share has gone up 12 years in a row, to $2.03. It has 12% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +2.3% vs 2024
- Ticker
- ZTS · NYSE
- Sector
- Health Care
- Sub-industry
- Pharmaceuticals
- Headquarters
- Parsippany, New Jersey
- Founded
- 1952
- In the S&P 500 since
- June 21, 2013
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Zoetis Inc. · CIK 0001555280
Revenue and net income
Revenue went from $4.23B in 2011 to $9.47B in 2025.
Diluted earnings per share
Diluted EPS went from $0.49 in 2011 to $6.02 in 2025. Ten-year growth: 24.4% a year.
Dividends per share
Raised 12 years in a row, every year from 2014 to 2025. Ten-year growth: 19.4% a year.
Shares outstanding
11.6% fewer shares in 2025 than in 2015 (502M → 444M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $2.28B in 2025, 24.1% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $9.47B | $2.67B | 28.2% | $6.02 | $2.03 | 444M | $2.9B | $621M | $2.28B |
| 2024 | $9.26B | $2.49B | 26.9% | $5.47 | $1.80 | 455M | $2.95B | $655M | $2.3B |
| 2023 | $8.54B | $2.34B | 27.4% | $5.07 | $1.56 | 462M | $2.35B | $732M | $1.62B |
| 2022 | $8.08B | $2.11B | 26.2% | $4.49 | $1.35 | 470M | $1.91B | $586M | $1.33B |
| 2021 | $7.78B | $2.04B | 26.2% | $4.27 | $1.07 | 477M | $2.21B | $477M | $1.74B |
| 2020 | $6.67B | $1.64B | 24.5% | $3.42 | $0.85 | 479M | $2.13B | $453M | $1.67B |
| 2019 | $6.26B | $1.5B | 24.0% | $3.11 | $0.69 | 482M | $1.79B | $460M | $1.33B |
| 2018 | $5.83B | $1.43B | 24.5% | $2.93 | $0.54 | 487M | $1.79B | $338M | $1.45B |
| 2017 | $5.31B | $864M | 16.3% | $1.75 | $0.44 | 493M | $1.35B | $224M | $1.12B |
| 2016 | $4.89B | $821M | 16.8% | $1.65 | $0.39 | 498M | $713M | $216M | $497M |
| 2015 | $4.76B | $339M | 7.1% | $0.68 | $0.34 | 502M | $664M | $224M | $440M |
| 2014 | $4.79B | $583M | 12.2% | $1.16 | $0.30 | 502M | $626M | $180M | $446M |
| 2013 | $4.56B | $504M | 11.1% | $1.01 | $0.27 | 500M | $681M | $184M | $497M |
| 2012 | $4.34B | $436M | 10.1% | $0.87 | $0.00 | 500M | $454M | $126M | $328M |
| 2011 | $4.23B | $245M | 5.8% | $0.49 | $0.00 | 500M | $497M | $135M | $362M |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Pharmaceuticals companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.